Follicular Lymphoma
📧 Sign up to get email alerts when something new happens for Follicular Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2012-08-02Clinical Trial Update: Zevalin® First Line in Follicular Lymphoma [Phase 2]
Phase 2 trial evaluating Zevalin (ibritumomab tiuxetan) as first-line therapy for Follicular Lymphoma; no results or current status are prov…
-
CLINICAL_TRIALS trial_result · 2012-07-02Clinical Trial Update: Chemotherapy Plus Interferon Alfa Alone or With Radiation Therapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma [Phase 3]
Phase 3 trial investigated chemotherapy with interferon alfa, with or without radiation therapy and peripheral stem cell transplantation, fo…
-
CLINICAL_TRIALS trial_result · 2012-06-26Clinical Trial Update: A Study of Rituximab Alternative Dosing Rate in Patients With Previously Untreated Diffuse Large B-cell or Follicular Non-Hodgkin's Lymphoma (RATE) [Phase 3]
Phase 3 study evaluating alternative dosing rate of rituximab in previously untreated diffuse large B-cell lymphoma and follicular lymphoma;…
-
CLINICAL_TRIALS trial_result · 2012-02-15Clinical Trial Update: Study to Treat Relapsed Follicular Non-Hodgkin's Lymphoma With Radiation and Bexxar [Phase 2]
Phase 2 study evaluating radiation therapy plus Bexxar (tositumomab) for relapsed follicular non-Hodgkin's lymphoma; the trial was terminate…
-
CLINICAL_TRIALS trial_result · 2012-02-03Clinical Trial Update: Study of the BiovaxId Tumor Derived Idiotype Vaccine in Patients With Follicular Lymphoma [Phase 3]
Phase 3 trial evaluating BiovaxID, a tumor-derived idiotype vaccine, in follicular lymphoma is ongoing with the trial status listed as unkno…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2011-12-21FDA Approved: REVLIMID — Supplemental Application (Celgene Corporation)
The FDA approves a supplemental application for Revlimid (lenalidomide) submitted by Celgene Corporation, updating regulatory status for the…
-
CLINICAL_TRIALS trial_result · 2011-12-08Clinical Trial Update: HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to Rituximab [Phase 2]
Phase 2 trial results for HuMax-CD20 (ofatumumab) in rituximab-refractory follicular lymphoma are reported. The study has completed and resu…
-
CLINICAL_TRIALS trial_result · 2011-12-07Clinical Trial Update: Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma [Phase 2]
Phase 2 clinical trial evaluating tipifarnib in relapsed or refractory lymphoma has completed with results posted in 2011.
-
FDA approval · 2011-11-18FDA Approved: ZEVALIN — Supplemental Application (Acrotech Biopharma Inc)
FDA approved a supplemental application for ZEVALIN (ibritumomab tiuxetan) submitted by Acrotech Biopharma Inc.
-
FDA label_change · 2011-10-28FDA Approved: LEUKERAN — Supplemental Application (Waylis Therapeutics LLC)
FDA supplemental application for Leukeran (chlorambucil) submitted by Waylis Therapeutics LLC.
-
CLINICAL_TRIALS research · 2011-10-13Clinical Trial Update: Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma [Phase 2]
A multicenter Phase II pilot trial assessing the efficacy and safety of LR-CHOP21 in elderly patients with untreated diffuse large B-cell ly…
-
CLINICAL_TRIALS trial_result · 2011-10-07Clinical Trial Update: A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other Low Grade, CD20+, Non-Hodgkin's Lymphomas [Phase 1, Phase 2]
A clinical trial update reports the Phase 1/2 study of dulanermin in combination with rituximab for follicular and other low-grade CD20+ non…
-
CLINICAL_TRIALS trial_result · 2011-10-06Clinical Trial Update: Idiotypic Vaccination for Follicular Lymphoma Patients [Phase 2]
This Phase 2 clinical trial is evaluating an idiotypic vaccination strategy for patients with Follicular Lymphoma in first relapse or progre…
-
CLINICAL_TRIALS trial_result · 2011-08-26Clinical Trial Update: Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) Patients [Phase 2]
Phase 2 trial evaluating ofatumumab in combination with CHOP chemotherapy in follicular lymphoma completed; results were posted in 2011.
-
CLINICAL_TRIALS trial_result · 2011-06-29Clinical Trial Update: Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies [Phase 2]
Phase II study assessing AT-101 as a single-agent therapy in relapsed or refractory B-cell malignancies has completed, reporting safety and …
-
CLINICAL_TRIALS trial_result · 2011-06-22Clinical Trial Update: A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma [Phase 2]
This Phase II clinical trial evaluated Velcade (bortezomib) in combination with bendamustine and rituximab for relapsed or refractory follic…
-
CLINICAL_TRIALS trial_result · 2011-02-21Clinical Trial Update: Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 study evaluating oblimersen sodium in combination with rituximab for recurrent B-cell non-Hodgkin lymphoma completed, with results…
-
CLINICAL_TRIALS research · 2011-02-15Clinical Trial Update: Multicentric Study, Three Randomized Arms (R-CVP vs R-CHOP vs R-FM),for Patients With Stage II-IV Follicular Lymphoma [Phase 3]
A Phase 3 multicenter randomized trial comparing three rituximab-containing regimens (R-CVP, R-CHOP, and R-FM) in patients with stage II-IV …
-
CLINICAL_TRIALS trial_result · 2011-01-07Clinical Trial Update: Mechanism of Action of Galiximab in Subjects With Previously Untreated Follicular Non-Hodgkin's Lymphoma [Phase 1]
Phase 1 study evaluating the mechanism of action of galiximab in previously untreated follicular non-Hodgkin's lymphoma; the trial status is…
-
CLINICAL_TRIALS trial_result · 2010-12-30Clinical Trial Update: Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating Rituxan (rituximab) and chemotherapy followed by Zevalin (ibritumomab tiuxetan) for low-grade follicular non-Hodgki…
-
CLINICAL_TRIALS trial_result · 2010-10-26Clinical Trial Update: A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma [Phase 2]
A Phase 2 study of Velcade (bortezomib) in relapsed or refractory follicular lymphoma has been terminated.
-
CLINICAL_TRIALS trial_result · 2010-10-18Clinical Trial Update: Immunochemotherapy, in Vivo Purging, PBSC Mobilization and Autotransplant in Relapsed or Refractory Follicular Lymphoma [Phase 2]
Phase 2 clinical trial evaluating immunochemotherapy, in vivo purging, peripheral blood stem cell mobilization, and autologous transplant in…
-
FDA approval · 2010-10-12FDA Approved: REVLIMID — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for REVLIMID (lenalidomide) submitted by Celgene Corporation.
-
CLINICAL_TRIALS trial_result · 2010-08-30Clinical Trial Update: Comparison Study of Rituximab Plus Sargramostim to Rituximab Alone for Relapsed Follicular B-cell Lymphoma, a Form of Non-Hodgkin's Lymphoma [Phase 2]
A Phase 2 trial comparing rituximab plus sargramostim versus rituximab alone in relapsed follicular B-cell lymphoma (a form of non-Hodgkin l…
-
CLINICAL_TRIALS trial_result · 2010-08-27Clinical Trial Update: Safety & Efficacy Study of AT-101 in Combination w/ Rituximab in Previously Untreated Grade I-II Follicular Non-Hodgkin's Lymphoma [Phase 2]
Phase 2 trial evaluating AT-101 in combination with Rituximab for previously untreated grade 1-2 follicular lymphoma, focusing on safety and…